AptarGroup 경영진
경영진 기준 점검 3/4
현재 CEO에 대한 정보가 충분하지 않습니다.
핵심 정보
Gael Touya
최고경영자
US$3.6m
총 보수
| CEO 급여 비율 | 18.10% |
| CEO 재임 기간 | no data |
| CEO 지분 보유율 | 0.05% |
| 경영진 평균 재임 기간 | 1.7yrs |
| 이사회 평균 재임 기간 | 7.3yrs |
최근 경영진 업데이트
Recent updates
내러티브 업데이트 • Aug 16
ATR: Recent Buybacks Will Support Future Upside Over The Coming Years
Analysts have lifted their price target on AptarGroup from $144 to $155, reflecting updated assumptions for slightly higher revenue growth, a modestly adjusted discount rate, and a broadly similar future P/E and profit margin profile. What’s in the News for AptarGroup AptarGroup reported that from April 1, 2026 to June 30, 2026, it repurchased 403,344 shares for US$50 million, representing 0.63% of its shares under the current buyback program.
내러티브 업데이트 • Aug 02
ATR: Share Repurchases And Refillable Packaging Will Support Attractive Future Returns
The analyst price target for AptarGroup has been adjusted from about $161.43 to about $165.29. Analysts point to updated assumptions around revenue growth, profit margins, and a slightly different forward P/E multiple as the key drivers of this change.Seeking Alpha • Jun 29
AptarGroup Has Fallen Enough (Rating Upgrade)
Summary AptarGroup is upgraded from 'sell' to 'hold' as valuation improves after a significant share price decline. ATR's Q1 revenue rose 10.8% to $982.9M, but most growth was driven by FX and acquisitions, not organic expansion. Cash flows and EBITDA improved despite margin compression and net profit declines, particularly due to Beauty segment strength. ATR trades at a premium to peers, justified by its niche positioning, but not enough for a 'buy' rating. Read the full article on Seeking Alpha분석 기사 • Jun 18
AptarGroup (ATR) Stock Could Be 25.5% Undervalued on Its Drug Delivery Growth Narrative
Why AptarGroup Stock Is Back On Investor Radars AptarGroup (ATR) has drawn interest after recent share price moves, with the stock gaining about 6% over the past month while still showing a decline over the past year. For investors tracking AptarGroup as a packaging and drug delivery supplier, those mixed return figures may prompt a closer look at how its current valuation lines up with recent business performance and market expectations. See our latest analysis for AptarGroup. With the share...
내러티브 업데이트 • Jun 17
ATR: Healthcare Packaging And Refillable Beauty Will Drive Future Upside Potential
The analyst price target for AptarGroup has been adjusted slightly to $211.14 from $211.25. Analysts cite updated assumptions for revenue growth, profit margins and the future P/E multiple as the main drivers of the change.내러티브 업데이트 • Jun 03
ATR: Healthcare Packaging And Refillable Beauty Will Support Future Upside Potential
Analysts have nudged their price target for AptarGroup higher by refining assumptions on revenue growth to 6.11%, profit margin to 9.78%, and a future P/E of 33.28x. This lifts their valuation outlook without changing the underlying fair value estimate of $211.25 per share.내러티브 업데이트 • May 12
ATR: Refillable Beauty And Nasal Drug Delivery Will Support Upside Potential
AptarGroup's updated analyst price target has edged down by about $1.54 to reflect slightly higher discount rate assumptions, along with modest adjustments to projected revenue growth, profit margins, and future P/E expectations, according to analysts. What's in the News AptarGroup and Clarins rolled out a custom reloadable airless packaging solution for Clarins Total Eye Lift Eye Cream, using Aptar Beauty’s patented Gaïa technology to support lower material usage while maintaining formula protection and a premium look.분석 기사 • May 03
Analyst Estimates: Here's What Brokers Think Of AptarGroup, Inc. (NYSE:ATR) After Its First-Quarter Report
Shareholders might have noticed that AptarGroup, Inc. ( NYSE:ATR ) filed its first-quarter result this time last week...내러티브 업데이트 • Apr 28
ATR: Nasal Therapies And Share Buybacks Will Support Future Upside
Analysts have kept their $144.00 price target on AptarGroup unchanged, citing relatively steady assumptions around discount rate, revenue growth, profit margin, and future P/E. These factors support the view that the stock’s current valuation framework still holds.내러티브 업데이트 • Apr 14
ATR: Nasal Drug Delivery Pipeline And Leadership Transition Will Shape Future Upside
Analysts have reaffirmed AptarGroup's price target at $144.00, citing updated assumptions for discount rates, revenue growth, profit margins and future P/E that together suggest a steady view of the company’s valuation. What's in the News AptarGroup’s Unidose Powder Nasal Spray System is being used in ENA Respiratory’s Phase II study of INNA-051, an investigational once-weekly nasal spray aimed at helping protect adults at higher risk from symptomatic viral respiratory infections (Key Developments).내러티브 업데이트 • Mar 30
ATR: Nasal And Eye Care Drug Delivery Will Drive Future Upside
Analysts have raised their price target on AptarGroup from $133 to $144. This reflects updated views on its fair value based on revised assumptions for discount rate, revenue growth, profit margin, and future P/E.내러티브 업데이트 • Mar 16
ATR: Share Repurchases Will Support Upside Potential In Drug Delivery Portfolio
Analysts have modestly revised their price target on AptarGroup, keeping fair value steady at about $212.79 while fine tuning assumptions on discount rate, revenue growth, profit margin and future P/E. This reflects updated views on the company’s risk profile and earnings potential.내러티브 업데이트 • Mar 02
ATR: Share Repurchases And Nasal Drug Delivery Portfolio Will Support Upside Potential
Analysts have trimmed their price target on AptarGroup slightly to about $213, reflecting updated assumptions around a modestly higher discount rate, a small change in estimated fair value and adjusted expectations for revenue growth, profit margins and future P/E levels. What's in the News AptarGroup issued earnings guidance for the first quarter of 2026, with earnings per share framed using a 1.18 EUR to US$ exchange rate assumption.내러티브 업데이트 • Feb 16
ATR: Drug Delivery Platforms And Buybacks Will Support Attractive Future Returns
Analysts have raised their price target for AptarGroup to $161.43 from $159.14, reflecting updated views on the company’s discount rate, revenue growth assumptions, profit margin outlook, and future P/E expectations. What's in the News AptarGroup issued earnings guidance for the first quarter of 2026, with earnings per share framed using a 1.18 EUR to US$ exchange rate assumption.내러티브 업데이트 • Feb 02
ATR: Nasal And Eye Care Drug Delivery Platforms Will Support Balanced Outlook
AptarGroup's analyst price target has changed from US$153 to US$133 as analysts incorporate updated assumptions for the discount rate, revenue growth, profit margin, and future P/E. What's in the News AptarGroup's LuerVax and Spray Divider nasal delivery systems are being used in CastleVax's Phase II clinical trial of CVAX-01, an intranasal COVID-19 vaccine candidate that is being assessed against an FDA approved injectable mRNA vaccine in around 200 U.S. adults, including higher risk and older participants (Key Developments).내러티브 업데이트 • Jan 19
ATR: Nasal And Eye Drug Delivery Platforms Will Support Attractive Future Returns
Analysts have trimmed their price target on AptarGroup to about $159 from roughly $161, reflecting slightly adjusted assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E that remain broadly consistent with prior views. What's in the News AptarGroup’s nasal vaccine delivery systems, LuerVax and Spray Divider, are being used in CastleVax’s Phase II clinical trial of CVAX-01, an intranasal COVID-19 vaccine candidate assessing safety, tolerability and immune response versus an FDA approved injectable mRNA vaccine in about 200 U.S. adults, including higher risk and older participants (Key Developments).내러티브 업데이트 • Jan 05
ATR: Pharma Nasal Delivery Momentum Will Drive Attractive Long Term Returns
Narrative Update on AptarGroup Analyst Price Target Analysts have modestly raised their price target for AptarGroup to approximately 161.43 dollars, reflecting slightly higher long term return expectations and a marginally richer future earnings multiple. What's in the News Aptar's Bidose liquid nasal spray system has been selected to deliver the newly FDA approved CARDAMYST nasal spray for acute PSVT episodes in adults, which underscores Aptar's role in emergency cardiovascular therapies (FDA announcement) The company completed a 1.50 million share repurchase, about 2.27 percent of shares outstanding, for approximately 227.34 million dollars under its October 2024 buyback program, which signals continued capital return to shareholders (company disclosure) Nasus Pharma extended and updated its long running collaboration with Aptar through a new master services agreement that covers development, analytical, regulatory, and consulting support for its intranasal epinephrine program using Aptar's unit dose powder nasal delivery system (Nasus Pharma announcement) A new supply agreement makes Aptar France the exclusive provider of UDSp devices to Nasus Pharma for its intranasal epinephrine products, with milestone payments and royalties tied to NDA submission, approval, and commercial sales (Nasus Pharma announcement) Valuation Changes Fair value estimate: unchanged at approximately 161.43 dollars per share, indicating no revision to the intrinsic value assessment.분석 기사 • Jan 02
We Like These Underlying Return On Capital Trends At AptarGroup (NYSE:ATR)
To find a multi-bagger stock, what are the underlying trends we should look for in a business? In a perfect world, we'd...내러티브 업데이트 • Dec 15
ATR: Share Repurchases And Nasal Drug Delivery Partnership Will Support Upside Potential
Narrative Update Analysts have modestly reduced their price target on AptarGroup, trimming fair value expectations from approximately $220.00 to about $213.03. They cite updated assumptions for slower revenue growth, slightly lower profit margins, and a higher future price to earnings multiple within their discounted cash flow framework.내러티브 업데이트 • Nov 30
ATR: Share Buyback and Expanded Pharma Partnerships Will Drive Future Upside
Analysts have slightly raised their price target for AptarGroup to $161.43, citing a modest increase in expected profit margins as well as an updated outlook on revenue growth and future price-to-earnings ratios. What's in the News Between July and September 2025, AptarGroup completed the repurchase of over 1.5 million shares for approximately $227.34 million as part of its ongoing buyback program (Company Filing).내러티브 업데이트 • Nov 16
ATR: Share Buyback and Pharma Supply Moves Will Unlock Upside
Narrative Update on AptarGroup Price Target Analysts have revised AptarGroup’s fair value estimate downward by approximately $9 to $161.43 per share, citing tempered growth projections and a modest increase in the discount rate as key factors behind the adjustment. What's in the News Completed share repurchases totaling 1,504,552 shares for $227.34 million under the buyback announced on October 10, 2024 (Buyback Tranche Update).내러티브 업데이트 • Nov 01
ATR: Expanded Partnership Agreements Will Drive Long-Term Healthcare Solutions
Analysts have revised their price target for AptarGroup downward from $177 to $170.71. They cited modest changes in discount rate expectations, a slight increase in projected revenue growth, and softer projected profit margins and future valuation multiples.분석 기사 • Oct 18
AptarGroup (NYSE:ATR) Is Increasing Its Dividend To $0.48
The board of AptarGroup, Inc. ( NYSE:ATR ) has announced that it will be increasing its dividend by 6.7% on the 13th of...내러티브 업데이트 • Sep 05
Advanced Drug Delivery And Sustainable Packaging Will Transform Global Healthcare
The uptick in AptarGroup’s consensus price target to $178.43 is primarily driven by a modest increase in its forward P/E multiple, while revenue growth expectations remain stable. What's in the News Held Analyst/Investor Day.CEO 보수 분석
| 날짜 | 총 보수 | 급여 | 회사 수익 |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | US$363m |
| Mar 31 2026 | n/a | n/a | US$387m |
| Dec 31 2025 | US$4m | US$653k | US$393m |
| Sep 30 2025 | n/a | n/a | US$419m |
| Jun 30 2025 | n/a | n/a | US$392m |
| Mar 31 2025 | n/a | n/a | US$370m |
| Dec 31 2024 | US$3m | US$602k | US$375m |
| Sep 30 2024 | n/a | n/a | US$336m |
| Jun 30 2024 | n/a | n/a | US$320m |
| Mar 31 2024 | n/a | n/a | US$313m |
| Dec 31 2023 | US$4m | US$573k | US$284m |
| Sep 30 2023 | n/a | n/a | US$281m |
| Jun 30 2023 | n/a | n/a | US$251m |
| Mar 31 2023 | n/a | n/a | US$232m |
| Dec 31 2022 | US$3m | US$561k | US$239m |
| Sep 30 2022 | n/a | n/a | US$238m |
| Jun 30 2022 | n/a | n/a | US$231m |
| Mar 31 2022 | n/a | n/a | US$223m |
| Dec 31 2021 | US$4m | US$607k | US$244m |
| Sep 30 2021 | n/a | n/a | US$240m |
| Jun 30 2021 | n/a | n/a | US$256m |
| Mar 31 2021 | n/a | n/a | US$243m |
| Dec 31 2020 | US$3m | US$571k | US$214m |
| Sep 30 2020 | n/a | n/a | US$209m |
| Jun 30 2020 | n/a | n/a | US$202m |
| Mar 31 2020 | n/a | n/a | US$234m |
| Dec 31 2019 | US$3m | US$524k | US$242m |
보상 대 시장: Gael의 총 보수(USD3.61M)는 US 시장에서 비슷한 규모 기업의 평균(USD8.47M)보다 낮습니다.
보상과 수익: Gael의 보상은 지난 1년 동안 회사 실적과 일치했습니다.
CEO
Gael Touya (56 yo)
no data
재임 기간
US$3,605,382
보수
Mr. Gael Touya is CEO, President & Director of AptarGroup, Inc. from September 1, 2026. Mr. Touya was President of Aptar Pharma at AptarGroup, Inc. since September 1, 2018 until September 1, 2026 and was i...
리더십 팀
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| CEO, President & Director | no data | US$3.61m | 0.050% $ 3.9m | |
| Executive VP & CFO | 1.7yrs | US$3.56m | 0.0020% $ 155.9k | |
| Director & Advisor | no data | US$10.23m | 0.38% $ 30.1m | |
| President of Aptar Beauty | 8yrs | US$2.24m | 0.025% $ 2.0m | |
| Executive VP of Strategic Group Development & President of Aptar Asia | 7.9yrs | US$2.20m | 0.018% $ 1.4m | |
| President of Aptar Closures | 10.3yrs | US$2.62m | 0.024% $ 1.9m | |
| Senior VP | no data | 데이터 없음 | 0.052% $ 4.1m | |
| Senior Vice President of Investor Relations & Communications | no data | 데이터 없음 | 데이터 없음 | |
| Executive VP | less than a year | 데이터 없음 | 0.0023% $ 184.4k | |
| Chief Human Resources Officer | 7.8yrs | 데이터 없음 | 0.041% $ 3.3m | |
| Head of Pharma Prescription | no data | 데이터 없음 | 데이터 없음 |
1.7yrs
평균 재임 기간
56yo
평균 나이
경험이 풍부한 관리: ATR의 경영진은 경험이 부족한 것으로 간주됩니다(평균 재임 1.7 년) — 신규 팀일 수 있습니다.
이사회 구성원
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| CEO, President & Director | no data | US$3.61m | 0.050% $ 3.9m | |
| Director & Advisor | 9.6yrs | US$10.23m | 0.38% $ 30.1m | |
| Independent Director | 15.3yrs | US$270.99k | 0.0078% $ 618.7k | |
| Independent Director | 8.6yrs | US$296.99k | 0.015% $ 1.2m | |
| Independent Chairperson | 5.3yrs | US$406.02k | 0.013% $ 1.0m | |
| Independent Director | 17.3yrs | US$266.99k | 0.027% $ 2.1m | |
| Independent Director | 16.3yrs | US$283.99k | 0.014% $ 1.1m | |
| Independent Director | 4yrs | US$278.99k | 0.015% $ 1.2m | |
| Independent Director | 7.3yrs | US$266.99k | 0.013% $ 1.0m | |
| Independent Director | 3.5yrs | US$266.99k | 0.0082% $ 652.0k | |
| Independent Director | 3yrs | US$270.99k | 0.0072% $ 566.5k |
7.3yrs
평균 재임 기간
60yo
평균 나이
경험이 풍부한 이사회: ATR의 이사회는 경험이 있음으로 간주됩니다(평균 재임 7.3 년).
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/09/21 11:06 |
| 종가 | 2026/09/18 00:00 |
| 수익 | 2026/06/30 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
AptarGroup, Inc.는 16명의 분석가가 다루고 있습니다. 이 중 8명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Ghansham Panjabi | Baird |
| Mark Wilde | BMO Capital Markets Equity Research |
| George Staphos | BofA Global Research |